Ying Cheng
Ying Cheng has led most of the Chinese small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.
Overview
Principal investigator of ASTRUM-005 (serplulimab plus chemotherapy, JAMA 2022), CAPSTONE-1 (adebrelimab plus chemotherapy, Lancet Oncology 2022) and the benmelstobart plus anlotinib trial in extensive-stage SCLC, as well as Chinese cohorts of global lung cancer studies; chairs CSCO's small cell lung cancer committee.
Pages like this
not linked directly; found by shared links- CompanyShanghai Henlius Biotech
Shares ASTRUM-005, Serplulimab, Small-cell lung cancer and the tag china.
- CompanyJiangsu Hengrui Pharmaceuticals
Shares Adebrelimab, CAPSTONE-1, Small-cell lung cancer and the tag china.
- CompanySino Biopharmaceutical (Chia Tai Tianqing)
Shares Anlotinib and the tag china.
- TrialALTER 0303
Shares Anlotinib and the tag china.
- TermLimited-stage vs extensive-stage (small-cell lung cancer)
Shares Adebrelimab, Serplulimab, Small-cell lung cancer.
- TrialIMpower133
Shares CAPSTONE-1, Small-cell lung cancer.
- TrialCASPIAN
Shares CAPSTONE-1, Small-cell lung cancer.
- ProductPlatinum + etoposide (EP / CE)
Shares ASTRUM-005, Small-cell lung cancer.